2024
Characterizing an Underdiagnosed Condition: Hemophilia in Females
Restrepo V, Prozora S, Louizos E, Van Doren L, Bona R. Characterizing an Underdiagnosed Condition: Hemophilia in Females. Blood 2024, 144: 2584-2584. DOI: 10.1182/blood-2024-210735.Peer-Reviewed Original ResearchPost-partum hemorrhageHeavy menstrual bleedingIron deficiency anemiaLow factor levelsClotting factor levelsHemophilia treatment centersHaemophilia carriersBlood transfusionHemophilia RegistryFactor deficiencyFactor levelsRates of heavy menstrual bleedingFrequency of blood transfusionLife-threatening bleedingFactor replacement therapyManagement of HCAnti-fibrinolytic agentDiagnosis of HCAge of diagnosisHemophilia B carriersYale-New Haven HospitalHealthcare disparitiesNormal factor VIIIHemophilia A carriersFactor activity
2021
Iron Infusion Reactions: Risk Factors and Real-World Experience
Butt A, Muradashvili T, Soliman S, Goshua G, Burns A, Bar N, Martin K, Borgman G, Bona R, Lee A, Neparidze N. Iron Infusion Reactions: Risk Factors and Real-World Experience. Blood 2021, 138: 4154. DOI: 10.1182/blood-2021-151048.Peer-Reviewed Original ResearchInfusion-related reactionsSeverity of IRRsHistory of CVDHistory of allergyCardiovascular diseaseBeta blockersOral ironPatient characteristicsRisk factorsLower oddsGreater oddsExact testAngiotensin-converting enzyme inhibitor useAssociation of CVDYale-New Haven HospitalEnzyme inhibitor useFirst-line therapyHeavy menstrual bleedingRetrospective chart reviewMajority of patientsAnti-inflammatory effectsMajor adverse effectsIron deficiency anemiaMultivariable regression analysisSeverity of reactions